Arrowhead Pharmaceuticals (NASDAQ: ARWR) suffered a major setback last year after it canceled the development of three experimental drug candidates for liver disease.
On Wednesday, Pasadena, CA-based Arrowhead—which houses its research and development operations in Madison, WI—shared data from... Read more »
[Updated 12/8/17, 4:27 pm. See below.] Boston-area cybersecurity startup Lexumo has shut down, a source close to the company confirmed to Xconomy.
After publication, CEO Dan McCall confirmed the news in an e-mail to Xconomy that said Lexumo ceased... Read more »
Ionic has introduced a new set of tools for developing mobile software applications, as the Madison, WI-based startup continues its effort to create revenue streams off of its sizeable user base.
The new suite of development tools, known as Ionic Pro... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
There’s just one week left before Xconomy’s latest biotech event, “San Diego Life Sciences 2022.” Don’t let the clock run out while you can still save some cash on a ticket.
Next Monday, December 11, we’re taking an inside look at... Read more »
On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease, rare blood disorders, and more. With part two, we’re... Read more »
Austin—Seven years ago, Scott Hanson was a student at University of Michigan who was hoping to raise a few hundred thousand dollars for Ambiq Micro, his fledgling startup that aimed to make low-powered microcontrollers.
Today, Ambiq is headquartered in... Read more »
They embrace the unfamiliar, overcome adversity, and through it all, make the most of limited resources. These characteristics describe many entrepreneurs. But they also describe immigrants, says Noubar Afeyan, CEO of Cambridge, MA, venture capital firm Flagship Pioneering.
It’s no coincidence... Read more »
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing.
As remarkable as they might seem, however, these medicines... Read more »